ATE423214T1 - Verfahren zur transfektion mittels calciumphosphat - Google Patents

Verfahren zur transfektion mittels calciumphosphat

Info

Publication number
ATE423214T1
ATE423214T1 AT02011731T AT02011731T ATE423214T1 AT E423214 T1 ATE423214 T1 AT E423214T1 AT 02011731 T AT02011731 T AT 02011731T AT 02011731 T AT02011731 T AT 02011731T AT E423214 T1 ATE423214 T1 AT E423214T1
Authority
AT
Austria
Prior art keywords
mixt
particles
transfection
calcium phosphate
host cell
Prior art date
Application number
AT02011731T
Other languages
English (en)
Inventor
Florian M Wurm
Martin Jordan
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE423214T1 publication Critical patent/ATE423214T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AT02011731T 1994-09-08 1995-08-30 Verfahren zur transfektion mittels calciumphosphat ATE423214T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/303,245 US5484720A (en) 1994-09-08 1994-09-08 Methods for calcium phosphate transfection
US08/430,533 US5593875A (en) 1994-09-08 1995-04-26 Methods for calcium phosphate transfection

Publications (1)

Publication Number Publication Date
ATE423214T1 true ATE423214T1 (de) 2009-03-15

Family

ID=23171182

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02011731T ATE423214T1 (de) 1994-09-08 1995-08-30 Verfahren zur transfektion mittels calciumphosphat

Country Status (4)

Country Link
US (3) US5484720A (de)
EP (1) EP1249497B1 (de)
AT (1) ATE423214T1 (de)
DE (1) DE69535917D1 (de)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484720A (en) * 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
GB9515356D0 (en) * 1995-07-26 1995-09-20 Medical Res Council Improvements in or relating to delivery of nucleic acid
US5843731A (en) * 1996-09-05 1998-12-01 Asahi Kogaku Kogyo Kabushiki Kaisha Method for purifying plasmid DNA on calcium phosphate compound
US5910584A (en) * 1996-09-05 1999-06-08 Asahi Kogaku Kogyo Kabushiki Kaisha Method for isolating plasmid DNA
US5972903A (en) * 1997-10-07 1999-10-26 Regents Of The University Of California Corporation Method for promoting angiogenesis using heparin and adenosine
CA2305726A1 (en) 1997-10-07 1999-04-15 Regents Of The University Of California Treating occlusive peripheral vascular disease and coronary disease with combinations of heparin and an adenoside a2 agonist, or with adenosine
US5973119A (en) * 1998-06-05 1999-10-26 Amgen Inc. Cyclin E genes and proteins
US6509174B2 (en) 1998-06-16 2003-01-21 Ecole Polytechnique Federal De Lausanne (Epfl) Cells, genetically modified with optical marker
GB9815819D0 (en) * 1998-07-22 1998-09-16 Secr Defence Transferring materials into cells and a microneedle array
US6344541B1 (en) * 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
IL143734A0 (en) * 1998-12-23 2002-04-21 Genentech Inc Transfectacons comprising calcium phosphate and a nucleic acid
US7708993B2 (en) * 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
US20020054914A1 (en) * 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
EP1471034A3 (de) * 1999-02-03 2005-03-02 Biosante Pharmaceuticals, Inc. Therapeutische kalzium-phosphat Partikel und Methoden zu deren Herstellung und Verwendung
US8624010B1 (en) 1999-02-03 2014-01-07 Steven K. Yoshinaga Nucleic acids encoding B7RP1
WO2000046147A2 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US20040258763A1 (en) * 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
AU773954B2 (en) 1999-02-03 2004-06-10 Amgen, Inc. Novel Polypeptides involved in immune response
WO2000058479A1 (en) 1999-03-26 2000-10-05 Amgen Inc. Beta secretase genes and polypeptides
US7408047B1 (en) * 1999-09-07 2008-08-05 Amgen Inc. Fibroblast growth factor-like polypeptides
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6900043B1 (en) * 1999-09-21 2005-05-31 Amgen Inc. Phosphatases which activate map kinase pathways
US20050239061A1 (en) * 2000-03-01 2005-10-27 Marshall William S Identification and use of effectors and allosteric molecules for the alteration of gene expression
US7514239B2 (en) 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
US7338773B2 (en) * 2000-04-14 2008-03-04 Millipore Corporation Multiplexed assays of cell migration
MXPA02012718A (es) * 2000-06-28 2003-10-06 Amgen Inc Moleculas semejantes a b7 y sus usos.
ES2391124T3 (es) 2000-06-28 2012-11-21 Amgen Inc. Moléculas de receptor de linfopoyetina estromal tímica y usos de las mismas
JP5610659B2 (ja) * 2000-07-21 2014-10-22 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 多成分生物学的輸送システム
JP4236925B2 (ja) 2000-11-28 2009-03-11 アムジエン・インコーポレーテツド 免疫応答に関与する新規ポリペプチド
US20030133988A1 (en) * 2001-08-07 2003-07-17 Fearon Karen L. Immunomodulatory compositions, formulations, and methods for use thereof
US20030185892A1 (en) * 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods
US20080206202A1 (en) * 2001-09-24 2008-08-28 Christopher Reid Methods for application of endogenous or exogenous stem/progenitor or their progeny for treatment of disease
US20030109037A1 (en) * 2001-09-24 2003-06-12 Reid Christopher Brian Methods for application of genetically-modified endogenous or exogenous stem/progenitor or their progeny for treatment of disease
AU2002363076A1 (en) * 2001-10-26 2003-05-06 Virtual Arrays, Inc. Assay systems with adjustable fluid communication
US7381375B2 (en) * 2001-10-26 2008-06-03 Millipore Corporation Assay systems with adjustable fluid communication
US20080187949A1 (en) * 2001-10-26 2008-08-07 Millipore Corporation Multiplexed assays of cell migration
US7662924B2 (en) * 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
WO2003072738A2 (en) * 2002-02-22 2003-09-04 Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
US20080207465A1 (en) * 2002-10-28 2008-08-28 Millipore Corporation Assay systems with adjustable fluid communication
KR100492292B1 (ko) * 2002-11-11 2005-05-27 오덕재 유전자의 세포내 도입을 위한 인산칼슘/핵산 복합체의 제조방법
WO2004060911A2 (en) * 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US7651694B2 (en) * 2004-02-13 2010-01-26 Nod Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of making and using same
ATE501252T1 (de) 2004-06-22 2011-03-15 Univ Illinois Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns
WO2006020580A2 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
CA2586035A1 (en) * 2004-11-01 2006-05-11 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles in use for aesthetic or cosmetic medicine, and methods of manufacture and use
US20060257492A1 (en) * 2005-05-13 2006-11-16 Depuy Products, Inc. Suspension of calcium phosphate particulates for local delivery of therapeutic agents
US20060257358A1 (en) * 2005-05-13 2006-11-16 Depuy Products, Inc. Suspension of calcium phosphate particulates for local delivery of therapeutic agents
WO2007030674A2 (en) * 2005-09-07 2007-03-15 Maxcyte, Inc. Use of nucleases to improve viability and enhance transgene expression in transfected cells
BRPI0810949A2 (pt) 2007-05-29 2015-10-27 Christopher B Reid "método de preparação de células multipotentes, auto-renovadoras, diferenciadoras ou resistentes a doenças, célula e vetor pra uso do método"
US8282918B2 (en) * 2007-07-30 2012-10-09 University Of Iowa Research Foundation Polynucleotides encoding RPA4/RPA32 hybrid polypeptides
AR069573A1 (es) * 2007-12-05 2010-02-03 Monsanto Technology Llc Promotores de proteinas quimericas y ricas en prolina para la expresion en plantas, donde el fenotipo es una menor infeccion por patogenos
US8034770B2 (en) 2008-06-04 2011-10-11 Amgen Inc. FGF21 polypeptides comprising two or more mutations
CA2739615C (en) 2008-10-10 2017-12-05 Amgen Inc. Fgf21 mutants comprising polyethylene glycol and uses thereof
WO2010129503A1 (en) * 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
WO2010129600A2 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
MX2011013903A (es) * 2009-06-17 2012-05-08 Amgen Inc Polipeptidos quimericos y usos de los mismos.
BR112012010755A2 (pt) 2009-11-05 2015-09-22 Proyecto Biomedicina Cima Sl constructo de gene que permite a expressão hepato-específica induzível de um polinucleotídeo de interesse em resposta a um agente indutor, vetor, genoma viral recombinante, vírion, método in vitro para a expressão de um polinucleotídeo de interesse em uma célula de origem hepática, composição farmacêutica e operador-promotor bi-direcional induzível adequado para a expressão hepato-específica induzível de dois polinucleotídeos de interesse por um agente indutor
EP2679234A3 (de) * 2009-12-02 2014-04-23 Amgen Inc. Bindeproteine zur Bindung an humanem FGFR1C, humanem beta-Klotho sowie humanem FGFR1C als auch humanem beta-Klotho
UA109888C2 (uk) * 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
CA2800065A1 (en) 2010-05-21 2011-11-24 Peptimed, Inc. Reagents and methods for treating cancer
WO2012095548A2 (es) 2011-01-13 2012-07-19 Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) Compuestos para el tratamiento de enfermedades neurodegenerativas
US9493744B2 (en) 2012-06-20 2016-11-15 Genentech, Inc. Methods for viral inactivation and other adventitious agents
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
HUE055862T2 (hu) 2016-04-20 2021-12-28 Centro De Investig Energeticas Készítmények és eljárások PKLR fokozott génexpressziójára
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
EP3554478B1 (de) 2016-12-16 2022-01-26 Delphi Scientific, LLC Geschichtete teilchen und verfahren dafür
SG11202002263TA (en) 2017-10-16 2020-04-29 Centro De Investigaciones Energeticas Medioambientales Y Tecnologicas Lentiviral vectors for delivery of pklr to treat pyruvate kinase deficiency
CR20200251A (es) 2017-11-17 2020-07-17 Iovance Biotherapeutics Inc Expansión de til de aspirados con aguja fina y biopsias por punción
EP3714041A1 (de) 2017-11-22 2020-09-30 Iovance Biotherapeutics, Inc. Expansion von peripheren blutlymphozyten (pbls) aus peripherem blut
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
EP3737743A1 (de) 2018-01-08 2020-11-18 Iovance Biotherapeutics, Inc. Verfahren zur erzeugung von til-produkten, die für tumorantigenspezifische t-zellen angereichert sind
US20190300575A1 (en) 2018-03-29 2019-10-03 Deetex, LLC Lytic peptide biosensor and methods of making and using the same
WO2019200167A1 (en) 2018-04-11 2019-10-17 Rocket Pharmaceuticals, Ltd. Compositions and methods for stem cell transplant
WO2019210131A1 (en) 2018-04-27 2019-10-31 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
BR112021002765A2 (pt) * 2018-08-16 2021-07-20 Spacecraft Seven, Llc métodos de produção para vetores virais
JP7854297B2 (ja) 2018-11-05 2026-05-01 アイオバンス バイオセラピューティクス，インコーポレイテッド 改良された腫瘍反応性ｔ細胞の選択
US12611427B2 (en) 2018-11-05 2026-04-28 Iovance Biotherapeutics, Inc. Treatment of NSCLC patients refractory for anti-PD-1 antibody
MY210603A (en) 2018-11-05 2025-10-01 Iovance Biotherapeutics Inc Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
WO2020096927A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
CA3123392A1 (en) 2018-12-19 2020-06-25 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
WO2020180733A1 (en) 2019-03-01 2020-09-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
EP4048295A1 (de) 2019-10-25 2022-08-31 Iovance Biotherapeutics, Inc. Genbearbeitung von tumorinfiltrierenden lymphozyten und deren verwendungen in der immuntherapie
PH12022551022A1 (en) 2019-10-28 2023-03-06 Medimmune Ltd Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
US12516291B2 (en) 2019-12-11 2026-01-06 Iovance Biotherapeutics, Inc. Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
CA3176826A1 (en) 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
CA3177413A1 (en) 2020-05-04 2021-11-11 Michelle SIMPSON-ABELSON Selection of improved tumor reactive t-cells
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
EP4259164A1 (de) 2020-12-11 2023-10-18 Iovance Biotherapeutics, Inc. Behandlung von krebspatienten mit tumorinfiltrierenden lymphozytentherapien in kombination mit braf-hemmern und/oder mek-hemmern
EP4262827A1 (de) 2020-12-17 2023-10-25 Iovance Biotherapeutics, Inc. Behandlung von krebs mit tumorinfiltrierenden lymphozyten
AU2021401302A1 (en) 2020-12-17 2023-07-06 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
WO2022165260A1 (en) 2021-01-29 2022-08-04 Iovance Biotherapeutics, Inc. Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
US20240191191A1 (en) 2021-03-19 2024-06-13 Iovance Biotherapeutics, Inc. Methods for infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
CA3213080A1 (en) 2021-03-23 2022-09-29 Krit RITTHIPICHAI Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
JP2024512029A (ja) 2021-03-25 2024-03-18 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｔ細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用
CA3215830A1 (en) 2021-04-19 2022-10-27 Rafael CUBAS Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
JP2024519029A (ja) 2021-05-17 2024-05-08 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
EP4373270A2 (de) 2021-07-22 2024-05-29 Iovance Biotherapeutics, Inc. Verfahren zur kryokonservierung von festen tumorfragmenten
JP2024527961A (ja) 2021-07-28 2024-07-26 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｋｒａｓ阻害剤と併用した腫瘍浸潤リンパ球療法によるがん患者の治療
WO2023039488A1 (en) 2021-09-09 2023-03-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
WO2023077015A2 (en) 2021-10-27 2023-05-04 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
CA3237410A1 (en) 2021-11-10 2023-05-19 Friedrich Graf Finck VON FINCKENSTEIN Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
EP4469065A1 (de) 2022-01-28 2024-12-04 Iovance Biotherapeutics, Inc. Zusammensetzungen und verfahren für cytokinassoziierte tumorinfiltrierende lymphozyten
CA3243416A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. TUMOR INFILTRATION LYMPHOCYTES MODIFIED TO EXPRESS PAYLOADS
WO2023196877A1 (en) 2022-04-06 2023-10-12 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2025512401A (ja) 2022-04-15 2025-04-17 アイオバンス バイオセラピューティクス，インコーポレイテッド 特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス
CA3251533A1 (en) 2022-05-10 2023-11-16 Iovance Biotherapeutics, Inc. TREATMENT OF CANCER PATIENTS WITH TUMOR-INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH AN IL-15R AGONIST
US20260021181A1 (en) 2022-08-01 2026-01-22 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
EP4583889A1 (de) 2022-09-09 2025-07-16 Iovance Biotherapeutics, Inc. Verfahren zur erzeugung von til-produkten mit pd-1/tigit talen-doppelknockdown
EP4583890A1 (de) 2022-09-09 2025-07-16 Iovance Biotherapeutics, Inc. Verfahren zur erzeugung von til-produkten mit pd-1/tigit talen-doppelknockdown
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
EP4612277A1 (de) 2022-11-04 2025-09-10 Iovance Biotherapeutics, Inc. Verfahren zur expansion von tumorinfiltrierenden lymphozyten (til) im zusammenhang mit cd39/cd103-auswahl
JP2025539816A (ja) 2022-11-21 2025-12-09 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の増幅のための２次元プロセス及びそれからの治療法
JP2025539712A (ja) 2022-11-21 2025-12-09 アイオバンス バイオセラピューティクス，インコーポレイテッド 遺伝子編集されたｔ細胞の増殖能を評価するための方法
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
WO2025054540A1 (en) 2023-09-08 2025-03-13 Iovance Biotherapeutics, Inc. Methods of gene-editing using programmable nucleases
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
WO2026050217A2 (en) 2024-08-27 2026-03-05 Iovance Biotherapeutics, Inc. Engineered artificial antigen presenting cells and lipid nanoparticles for tumor infiltrating lymphocyte expansion

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3684947D1 (de) * 1985-03-15 1992-05-27 Nat Res Dev Faktor-ix-protein.
US4968615A (en) * 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5484720A (en) * 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection

Also Published As

Publication number Publication date
US5633156A (en) 1997-05-27
US5484720A (en) 1996-01-16
US5593875A (en) 1997-01-14
DE69535917D1 (de) 2009-04-02
EP1249497B1 (de) 2009-02-18
EP1249497A2 (de) 2002-10-16
EP1249497A3 (de) 2004-03-17

Similar Documents

Publication Publication Date Title
ATE423214T1 (de) Verfahren zur transfektion mittels calciumphosphat
DE69432540D1 (de) Verfahren zur Herstellung von Nucleinsäuren aus einer biologischen Probe bei niedrigem pH und unter Verwendung einer Säureprotease
ATE411391T1 (de) Verfahren zur herstellung stresstoleranter pflanzen
ATE27463T1 (de) Verfahren zur in vitro transformation von pflanzenprotoplasten mit plasmid-dns.
WO1998033893A3 (en) Ribozymes cleaving epidermal growth factor receptors
DE60026844D1 (de) Verfahren zur herstellung von 3,3-dimethylbutanal
DE69936532D1 (de) Verfahren zum quantitativen nachweis von nukleinsäuren
ATE270250T1 (de) Stabiles, plättchenförmiges, calcitisches calciumcarbonat, verfahren zu dessen herstellung und seine verwendung
DE69733490D1 (de) Verfahren zur polyestern-biosynthese
DE60115225D1 (de) Verfahren zur bestimmung einer genfunktion
DK1141366T3 (da) Transfektaconer omfattende calciumphosphat og en nukleinsyre
ATE298747T1 (de) Verfahren zur herstellung von 5- hydroxybenzo(b)thiophen-3-carbonsäure
ATE228170T1 (de) Verfahren zur kalziumphosphat-transfektion
WO2002092786A3 (en) A helper dependent adenoviral vector system and methods for using the same
BRPI0409801A (pt) método para produzir ácido l-glutámico por fermentação
DE60207914D1 (de) Verfahren zur Herstellung von L-Glutaminsäure
ATE416257T1 (de) Promotoren für wachstums-differenzierungsfaktoren und deren verwendung
ATE234934T1 (de) Verfahren zur herstellung von einem beta-laktam antibiotikum
DE69614711D1 (de) Verfahren zur gewinnung von cephalexin
US5330904A (en) Method for mammalian cell transfection using 25-hydroxycholesterol
DE69924718D1 (de) Gen 62 des attenuierten windpocken-virusstammes oka und verfahren zur identifikation eines attenuierten, lebenden windpockenvirusstammes unter verwendung dieses genes.
WO2000000598A3 (en) Plant dwarfing
ATE269417T1 (de) Verfahren zur erkennung und messung von gespleisten nukleinsäuren
ATE76251T1 (de) Verfahren zur kultur von pflanzengewebe.
DE69923595D1 (de) Herstellung von proteinen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1249497

Country of ref document: EP